Status:
UNKNOWN
Development and Application of Molecular Evaluation Instrument for Lung Cancer Diagnosis and Treatment
Lead Sponsor:
Shanghai Pulmonary Hospital, Shanghai, China
Conditions:
Lung Cancer
Eligibility:
All Genders
18-75 years
Brief Summary
The precise diagnosis and treatment of lung cancer is not only a major national strategic need but also an urgent demand from the general public. The "three stages" of precise diagnosis and treatment ...
Eligibility Criteria
Inclusion
- Voluntarily participate in the clinical study; fully understand and be informed about this study, and sign the informed consent form (ICF); willing to comply with and have the ability to complete all trial procedures.
- Male or female participants aged 18-75 (inclusive) at the time of signing the ICF.
- The case group included patients diagnosed with lung cancer, including early-stage and advanced-stage patients; the control group consisted of healthy individuals without a history of lung cancer or related respiratory diseases.
- At least one measurable target lesion evaluated according to RECIST 1.1 criteria by the Institutional Review and Research Committee (IRRC).
- Patients provide eligible tumor tissue for histopathological testing as required.
- Relevant laboratory tests indicate tolerance to chemotherapy and immunotherapy.
Exclusion
- Patients with unclear diagnosis of lung cancer.
- Patients with contraindications to chemotherapy or immunotherapy.
- Patients with contraindications to lung tissue examination.
- Patients with other respiratory diseases within the year or concurrent respiratory system diseases (such as chronic obstructive pulmonary disease, bronchial asthma, etc.).
- Patients with other active malignant tumors within the year or concurrently.
- Patients with severe heart disease and patients with other severe diseases (such as liver dysfunction, renal dysfunction, etc.).
- Patients known to have a history of psychiatric drug abuse or drug addiction; patients with a history of alcohol abuse.
- Based on the investigator's judgment, patients have other factors that may lead to premature termination of this study.
Key Trial Info
Start Date :
November 7 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 31 2025
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06086587
Start Date
November 7 2023
End Date
October 31 2025
Last Update
October 17 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.